ResearchSafe

PE 22-28 and the TREK-1 channel research

Posted by optimizer_jenna in Research & News - 7 points, 4 comments.

I was reading some updates about TREK-1 channel blockers today and it actually made me think about PE 22-28. I know this is still very much in the preclinical stage, which makes me a bit skeptical about the hype, but the idea of targeting neuroplasticity through this specific mechanism is quite interesting.

The research suggests that blocking these potassium channels might lead to much faster antidepressant effects compared to traditional SSRIs by promoting synaptogenesis. Tbh, the speed of action is what catches my eye. Most of the things I have looked into for mood seem to take weeks to even start working, so the concept of a fast-acting peptide is very appealing from a research perspective.

However, since there is no established human dose and we really do not know the long-term safety profile, I am staying very cautious. It feels like one of those things that sounds amazing in a lab setting but might be much more complicated for a human brain. Has anyone else been following the spadin-derived research lately? I am curious if anyone has seen actual papers discussing the transition from animal models to human safety trials for these kinds of neuroplasticity agents.

Comments

  • zone2_nof1: Yeah I’ve been skimming the same stuff and the speed angle does grab attention. Anecdotally, I tried a low‑dose nasal spray of a related peptide a while back just to see if I felt any shift in mood or focus – nothing dramatic, just a slight bump in alertness for a couple of hours that could’ve been placebo. The jump from rodent synaptogenesis data to human safety is huge though, especially with ion‑channel modulators where off‑target effects on cardiac or neuronal excitability can pop up fast.
  • optimizer_jenna: I have not seen any human PK studies yet, which is exactly why I am so hesitant. Thank you for mentioning the off target effects on cardiac excitability, that is a VERY important point that I actually missed. It makes the rodent data feel even more distant. Tbh, your experience with the nasal spray makes me wonder if these effects are just too subtle to notice without a huge dose. Do you remember if the related peptide you used had a similar mechanism?
  • tracker169: I haven’t come across any human PK data for PE 22‑28 yet, just the rodent papers and a few early‑stage safety notes in the literature. I keep an eye on clinicaltrials.gov but nothing shows up so far. Maybe the work is still too early for phase 1.
  • optimizer_jenna: Thanks for checking clinicaltrials.gov – I did the same and saw nothing either. It really does seem pre‑clinical still. Do you know if any labs have announced plans for a first‑in‑human study, or are we just waiting for more rodent data?

Community discussion - research and educational context only. Not medical advice.